Investors
MacuCLEAR will grow through strategic alliances, consistent with the industry trend of large pharmaceutical and biotech companies seeking novel drugs to fill their product pipelines and diminishing intellectual property portfolios. The company intends to out-license its portfolio of novel drug formulations for eye disorders and will derive income from licensing fees, milestone payments and royalties.